Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 642

1.

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group.

Am J Kidney Dis. 2006 Nov;48(5):739-51.

PMID:
17059993
2.

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL.

Arch Intern Med. 2005 Apr 25;165(8):947-53.

PMID:
15851648
3.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group.

JAMA. 2001 Jun 6;285(21):2719-28.

PMID:
11386927
4.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group.

JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726.

PMID:
12435255
5.

Blood pressure control, drug therapy, and kidney disease.

Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER 3rd, Ojo A, Sika M, Wilkening B, Toto RD; African American Study of Kidney Disease and Hypertension Study Group Investigators.

Hypertension. 2005 Jul;46(1):44-50. Epub 2005 May 16.

6.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
7.

Lessons from the African-American Study of Kidney Disease and Hypertension: an update.

Toto RD.

Curr Hypertens Rep. 2006 Oct;8(5):409-12. Review.

PMID:
16965728
8.

Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study.

Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, Lash J, Cornish-Zirker D, Peterson G, Toto R, Kusek J, Appel L, Kendrick C, Gassman J; AASK group.

Am J Kidney Dis. 2007 Jul;50(1):78-89, 89.e1.

PMID:
17591527
9.
10.

Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group.

Ann Intern Med. 2006 Feb 7;144(3):172-80.

PMID:
16461961
11.

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2006 Sep;48(3):374-84. Epub 2006 Jul 24.

12.

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.

Thornley-Brown D, Wang X, Wright JT Jr, Randall OS, Miller ER, Lash JP, Gassman J, Contreras G, Appel LJ, Agodoa LY, Cheek D.

Arch Intern Med. 2006 Apr 10;166(7):797-805.

PMID:
16606818
13.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
14.

A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension.

Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr; AASK Study Group.

J Am Soc Nephrol. 2004 Dec;15(12):3175-83.

15.

Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.

Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M; African American Study of Kidney Disease and Hypertension Trial Study Group.

Am J Kidney Dis. 2006 Jun;47(6):956-64.

PMID:
16731290
16.

Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R.

Control Clin Trials. 1996 Aug;17(4 Suppl):3S-16S.

PMID:
8889350
17.
18.

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.

Nephrol Dial Transplant. 2008 Feb;23(2):573-9. Epub 2007 Nov 4.

19.

Recommendations for the management of special populations: racial and ethnic populations.

Ferdinand KC.

Am J Hypertens. 2003 Nov;16(11 Pt 2):50S-54S. Review.

PMID:
14625162
20.

Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate.

Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J Jr; African-American Study of Hypertension and Kidney Disease.

Am J Kidney Dis. 2001 Oct;38(4):744-53. Erratum in: Am J Kidney Dis 2002 Feb;39(2):444.

PMID:
11576877
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk